Neumora reports Q2 2026 results, names Joshua Pinto CEO as Berns moves to Executive Chair

Neumora Therapeutics announced on August 14, 2026 that Paul L. Berns, the company's current chief executive officer, will become Executive Chairperson of the Board, while Joshua Pinto, Ph.D., the company's current President, will succeed Berns as chief executive officer effective August 14, 2026¹. The board approved the leadership transition on August 12, 2026.¹ Pinto will also continue serving as president.¹ The board also approved Pinto's appointment as a Class III director effective on the transition date, for a term running until the 2029 annual meeting of stockholders.¹

Separately, Neumora said it appointed Doron Sagman, M.D., FRCPC, as chief medical officer. Sagman brings more than 20 years of leadership experience spanning clinical development, medical affairs, regulatory strategy, and psychiatry, according to the company.¹

On the pipeline, Neumora expects to submit an IND for NMRA-215 in the fourth quarter of 2026 and to initiate a Phase 1 study by the end of 2026.¹ For NMRA-511, the company is running a Multiple Ascending Dose expansion cohort testing higher doses in healthy elderly participants, with data expected in the fourth quarter of 2026; Neumora also plans to initiate a Phase 2 study of NMRA-511 in Alzheimer's disease agitation by the end of 2026.¹ For NMRA-898, the company is conducting a MAD study in healthy volunteers and patients with stable schizophrenia, with data expected in the second half of 2026.¹

On finances, Neumora had cash and cash equivalents of $116.8 million as of June 30, 2026.¹ The company said this is expected to fund operations into the third quarter of 2027.¹ R&D expenses were $29.3 million for the quarter, down from $38.7 million a year earlier¹, and net loss was $43.1 million, compared with $52.7 million in the same period of 2025.¹